Second, findings obtained did not show the superiority of one biomarker over the other but rather the combination of ctDNA with PSA kinetics may improve outcome prediction, for example, adding some information about response to treatment in a subgroup of prostate cancer patients without target lesions, such as those with only bone metastatic disease, in which CT scan and bone scan could lack of sensibility and specificity in detection of response or progression. The gene discussed is KLK3; the disease is prostate carcinoma.